Your choices go into the PDF (cover and captions); this bar does not.
Rebalix
Comparison report · official data side by side

AQUIL vs SP5C


AQUILFineco AM Amundi S&P 500 UCITS ETF Acc
IE0002DC0IL1 · Equity · United States · Large cap
SP5CAmundi Core S&P 500 Swap UCITS ETF Acc
LU1135865084 · Equity · United States · Large cap
Open the interactive comparison on rebalix.com →

Comparison window: · currency: 🇪🇺 EUR · inflation: 🇮🇹 Italy · distributions: reinvested where declared

Report produced on 5 September 2026 · data as of the dates shown per section
Sources: official issuer documents (KID, factsheet, declared NAV series and holdings), ESMA register, ECB rates, Eurostat
Public methodology: rebalix.com/en/methodology

Informational document generated by rebalix.com — facts side by side, no recommendations. It does not constitute investment advice or investment research under Directive 2014/65/EU (MiFID II). Past performance is not indicative of future results.

RebalixAQUIL vs SP5C · report of 5 September 2026

The funds at a glance

From official issuer documents and the ESMA register
AQUILIE0002DC0IL1Fineco AM Amundi S&P 500 UCITS ETF AccEquity · United States · Large cap
Declared index
S&P 500 Net Total Return Index
TER
0.10%
Transaction (KID)
0.00%
Fund size
1 mln EUR
Launch
21 Jul 2026
Currency
EUR
Replication
Physical
Hedging
No
Holdings
1
Effective 🇮🇹 rate
26.00%
SP5CLU1135865084Amundi Core S&P 500 Swap UCITS ETF AccEquity · United States · Large cap
Declared index
S&P 500 Net Total Return Index
TER
0.05%
Transaction (KID)
0.00%
Fund size
15.9 mld EUR
Launch
9 Dec 2014
Currency
USD
Replication
Synthetic (swap)
Hedging
No
Holdings
495
Effective 🇮🇹 rate
26.00%

Tracking difference — year by year

Fund minus index, from issuer-declared series (complete calendar years). Each measures adherence to its OWN index.
AQUILn/d
not honestly computable
SP5C3y avg: +0.45%/anno
2025
−0.02%
2024
+0.76%
2023
+0.60%
2022
+0.58%
2021
−0.49%
2020
+0.83%
Rebalix · AQUIL vs SP5Csection 1 of 2
RebalixAQUIL vs SP5C · report of 5 September 2026

Full comparison table

"—" = not published by the source, never estimated
AQUILFineco AM Amundi S&P 500 UCITS ETF Acc · IE0002DC0IL1 · Equity · United States · Large cap
SP5CAmundi Core S&P 500 Swap UCITS ETF Acc · LU1135865084 · Equity · United States · Large cap
MetricAQUILSP5CNote
Identity
CategoryEquity · United States · Large capEquity · United States · Large capRebalix engine classification
ReplicationPhysicalSynthetic (swap)as declared by the issuer
Currency hedgingNoNosource: class name, factsheet
Income policyaccumulatingaccumulating
Costs
TER0.10%0.05%from the KID
Transaction costs (KID)0.00%0.00%internal
All-in cost0.10%0.05%TER + transaction
Tracking difference (3a)+0.45%vs its OWN index
Performance in euro (ECB rates)
1 year+22.6%
3 years+65.5%
5 years+86.3%
10 years+298.7%— = series younger than the window
Risk · last 3 years
Volatility (ann.)+15.71%
Max drawdown−18.55%
Sharpe1.13risk-free = ECB MRO avg
Sortino1.66like Sharpe, downside only
Italian taxation
Effective capital-gains rate26.00%26.00%white list, current half-year
Documents & exchanges
Listing venues110ESMA register
Borsa Italiana tickerAQUILSP5C
Indicative cumulative cost: on 10,000 euro over 5 years (stated assumption: 5%/yr growth, cost = TER + transaction) ~66 euro AQUIL · ~32 euro SP5C. Broker costs not included.

Disclaimer

This document is for information only and does not constitute investment advice under Directive 2014/65/EU (MiFID II), investment research, a personal recommendation, or an offer or solicitation to buy or sell financial instruments.

Past performance is not indicative of, nor a guarantee of, future results. The value of an investment can go down as well as up and investors may not get back the capital invested. Euro returns are affected by currency fluctuations.

Before any investment decision, read the KID and the Prospectus, available from the issuers. Tax treatment depends on individual circumstances and may change.

Data come from official issuer documents and public registers, following the public methodology at rebalix.com/en/methodology. "—" fields were not published by the source and have not been estimated. Rebalix receives no compensation from the issuers mentioned.

Rebalix · AQUIL vs SP5Csection 2 of 2